{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-020404","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.982539+00:00","generated_at":"2026-05-25T12:45:07.998824+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cryoport reports FY 2024 revenue $228.4M (-2% YoY); guides FY 2025 revenue $240-250M","bullets":["FY 2024 revenue $228.4M (down 2% YoY); Q4 revenue $59.5M (up 4% YoY).","Net loss attributable to common shareholders FY 2024 $122.8M ($2.49/sh) vs $107.6M ($2.21/sh) in FY 2023.","Commercial Cell & Gene therapy revenue grew 20% YoY to $25.9M in FY 2024.","Adjusted EBITDA negative $15.1M in FY 2024 vs negative $8.3M in FY 2023.","FY 2025 revenue guidance $240M-$250M; gross margin improved to 45.8% in Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-020404","json":"https://secwatch.observer/filing/0001104659-25-020404.json","markdown":"https://secwatch.observer/filing/0001104659-25-020404.md","text":"https://secwatch.observer/filing/0001104659-25-020404.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465925020404/0001104659-25-020404-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465925020404/tm258273d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T12:45:07.998824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}